It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANSLY’s FA Score shows that 1 FA rating(s) are green whileBRSYF’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANSLY’s TA Score shows that 1 TA indicator(s) are bullish while BRSYF’s TA Score has 0 bullish TA indicator(s).
ANSLY (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while BRSYF (@Medical/Nursing Services) price change was +61.47% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.53%. For the same industry, the average monthly price growth was -0.29%, and the average quarterly price growth was +4.24%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.37%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +4.58%.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+1.37% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
ANSLY | BRSYF | ANSLY / BRSYF | |
Capitalization | 3.04B | 247M | 1,232% |
EBITDA | 262M | 6.57M | 3,986% |
Gain YTD | -5.644 | 74.286 | -8% |
P/E Ratio | 24.26 | 39.21 | 62% |
Revenue | 1.85B | 43.5M | 4,262% |
Total Cash | 52.9M | 71.6M | 74% |
Total Debt | 279M | 5.57M | 5,013% |
ANSLY | BRSYF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 95 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 65 | |
SMR RATING 1..100 | 86 | 76 | |
PRICE GROWTH RATING 1..100 | 57 | 36 | |
P/E GROWTH RATING 1..100 | 35 | 100 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANSLY's Valuation (18) in the null industry is somewhat better than the same rating for BRSYF (71). This means that ANSLY’s stock grew somewhat faster than BRSYF’s over the last 12 months.
BRSYF's Profit vs Risk Rating (65) in the null industry is somewhat better than the same rating for ANSLY (100). This means that BRSYF’s stock grew somewhat faster than ANSLY’s over the last 12 months.
BRSYF's SMR Rating (76) in the null industry is in the same range as ANSLY (86). This means that BRSYF’s stock grew similarly to ANSLY’s over the last 12 months.
BRSYF's Price Growth Rating (36) in the null industry is in the same range as ANSLY (57). This means that BRSYF’s stock grew similarly to ANSLY’s over the last 12 months.
ANSLY's P/E Growth Rating (35) in the null industry is somewhat better than the same rating for BRSYF (100). This means that ANSLY’s stock grew somewhat faster than BRSYF’s over the last 12 months.
ANSLY | BRSYF | |
---|---|---|
RSI ODDS (%) | 1 day ago33% | 1 day ago14% |
Stochastic ODDS (%) | N/A | 1 day ago23% |
Momentum ODDS (%) | 1 day ago42% | N/A |
MACD ODDS (%) | N/A | N/A |
TrendWeek ODDS (%) | 1 day ago38% | 1 day ago32% |
TrendMonth ODDS (%) | 1 day ago44% | 1 day ago32% |
Advances ODDS (%) | N/A | N/A |
Declines ODDS (%) | N/A | N/A |
BollingerBands ODDS (%) | N/A | N/A |
Aroon ODDS (%) | 1 day ago48% | N/A |
A.I.dvisor indicates that over the last year, ANSLY has been loosely correlated with BRSYF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ANSLY jumps, then BRSYF could also see price increases.
Ticker / NAME | Correlation To ANSLY | 1D Price Change % | ||
---|---|---|---|---|
ANSLY | 100% | N/A | ||
BRSYF - ANSLY | 61% Loosely correlated | N/A | ||
IOBCF - ANSLY | 43% Loosely correlated | N/A | ||
VERO - ANSLY | 33% Poorly correlated | -5.31% | ||
FSPKF - ANSLY | 26% Poorly correlated | N/A | ||
PDEX - ANSLY | 22% Poorly correlated | +4.96% | ||
More |
A.I.dvisor indicates that over the last year, BRSYF has been loosely correlated with ANSLY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if BRSYF jumps, then ANSLY could also see price increases.
Ticker / NAME | Correlation To BRSYF | 1D Price Change % | ||
---|---|---|---|---|
BRSYF | 100% | N/A | ||
ANSLY - BRSYF | 61% Loosely correlated | N/A | ||
IOBCF - BRSYF | 39% Loosely correlated | N/A | ||
VERO - BRSYF | 30% Poorly correlated | -5.31% | ||
WUXIF - BRSYF | 27% Poorly correlated | +84.43% | ||
SNWV - BRSYF | 25% Poorly correlated | +2.20% | ||
More |